Name
#26 - Specific Vaccinations Exacerbate Immune Thrombocytopenia
Date & Time
Monday, February 12, 2024, 12:00 PM
Description

A case report describing a patient with a temporal association of recurrent ITP following 2 different brands of COVID-19 mRNA vaccines and high dose influenza vaccine in a patient with a known history of ITP. Case Description: We present a 67-year-old female with a known history of stable ITP who presented for evaluation of acute drop in platelets following vaccination with her first mRNA COVID-19 monovalent booster. She was hospitalized due to bleeding risk and her platelets recovered following aggressive therapy. Patient had two subsequent drops in her platelet count after a different brand of mRNA COVID-19 monovalent booster vaccine as well as her first high dose influenza vaccine which, both with spontaneous resolution. Patient previously tolerated the primary mRNA COVID-19 monovalent vaccine series and standard dose influenza vaccines. She tolerated her third mRNA COVID-19 booster without complications. Ultimately, recommendations were made to administer immunizations individually, separate future COVID-19 vaccine doses by 6 months, use previously tolerated brands of influenza vaccine, and to monitor platelet counts before and after subsequent vaccines.

Location Name
Prince Georges Exhibit Hall A/B
Content Presented on Behalf of
DHA
Learning Outcomes
Following this session, the attendee will be able to:


1.Describe a rare case of recurrent Immune thrombocytopenia following immunization.
2.Propose strategies to mitigate risk of recurrent ITP following immunization.
3.Recognize the importance of careful monitoring of vulnerable patient groups for recurrent ITP following immunizations
Session Type
Posters
Dropdown Content Presented On Behalf Of:
DHA